Opening
The biotech group was not only one of the worst-performing sectors in 2016, but it was no better in 2015 either. The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) is down nearly 30% from its all-time high in July of 2015. Things couldn't look bleaker for the sector going into 2017, as President-Elect Trump has said he wanted to take on drug pricing. Unfortunately, one of the biggest mysteries is just how he plans to go about doing this? Does it come in the form regulation, price caps, or patent law? How do you go about taking on drug prices by solving the problem without stripping the sector of its incentive to spend millions and sometimes billion of dollars to develop some of these new life-saving drugs?
From listening to the soon to be president and his viewpoints on health insurance and even the Lockheed Martin (NYSE:LMT)…
